Could a liver drug tame polyps in rare gut condition?

NCT ID NCT05223036

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether obeticholic acid, a drug already used for liver disease, can safely reduce the number of polyps in the small bowel and colon in people with familial adenomatous polyposis (FAP). FAP is a rare genetic condition that greatly raises the risk of intestinal cancer. The trial planned to enroll 15 participants but was terminated early, so its findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obeticholic acid
What this could lead to: If it works, this could point toward a way to reduce polyp burden and lower cancer risk in people with FAP.
What could go wrong: This is an early, small trial (15 participants) that was terminated, so results are limited. The drug may not reduce polyps and could cause side effects like itching or liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENUATED FAMILIAL ADENOMATOUS POLYPOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenomatous Polyposis Coli attenuated familial adenomatous polyposis carcinoma of duodenum classic familial adenomatous polyposis colorectal carcinoma colorectal neoplasm duodenum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENUATED FAMILIAL ADENOMATOUS POLYPOSIS COLORECTAL CARCINOMA DUODENAL CARCINOMA FAMILIAL ADENOMATOUS POLYPOSIS

Contacts and locations

Show contact details

Locations

Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Michigan Rogel Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Puerto Rico

San Juan, 00936, Puerto Rico

More trials for these conditions

Other studies related to the condition(s) this trial covers.